CALCIMAR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALCIMAR is an injectable small-molecule drug approved in 1978 by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, limiting clinical context. As a legacy NDA product, it represents a mature therapeutic option in its market segment.
LOE Approaching
Product is in late lifecycle with approaching loss of exclusivity; commercial team likely focused on maximizing remaining branded revenue and managing transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the mature, stable nature of CALCIMAR with no active hiring surge. Career advancement on this product is tied to defensive commercial execution rather than growth opportunities.
Brand ManagerField Sales Representative
Worked on CALCIMAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.